IP Library › Granted Patent US 12,486,226
Granted Patent B2
US 12,486,226 · App. 17/155,569 · Granted Dec 2, 2025

Cannabinoid derivatives

Inventor: Crist Filer (Somerville, MA)
Assignee: Revvity Health Sciences, Inc.
C07D205/04C07B59/001C07C39/23C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,486,226
App. No.
17/155,569
Granted
Dec 2, 2025
Kind
B2
Abstract

This disclosure provides 8,9-dihydrocannabinoid derivatives, deuterated cannabinoid derivatives, and tritiated cannabinoid derivatives. The disclosure also provides compositions, methods of use, and processes of preparation of the foregoing derivatives.

Claims (24)

1 . A compound of formula

or a pharmaceutically acceptable salt or solvate thereof.

2 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

3 . A compound of Formula (1)

or a pharmaceutically acceptable salt or solvate thereof,

wherein Y 1 and Y 2 are each independently hydrogen or deuterium,

is a single bond,

and

Z is

4 . The compound of claim 3 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof, wherein one or both of Y 1 and Y 2 is deuterium.

5 . The compound of claim 3 , wherein each of Y 1 and Y 2 is hydrogen.

6 . A pharmaceutical composition comprising a compound of claim 3 , or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable excipients.

7 . A compound of Formula (2)

or a pharmaceutically acceptable salt or solvate thereof,

wherein Y 1 and Y 2 are each independently hydrogen or tritium,

is a single bond,

and Z 1 and Z 2 are are each independently hydrogen or tritium,

provided that the compound comprises tritium,

and

Z is

8 . The compound of claim 7 , wherein the compound of Formula II is

or a pharmaceutically acceptable salt or solvate thereof, wherein is a single bond and wherein at least one of Z 1 and Z 2 is tritium.

9 . The compound of claim 7 , wherein each of Y 1 and Y 2 is hydrogen.

Assignments (2)
CHANGE OF NAME Recorded Mar 25, 2024
From: PERKINELMER HEALTH SCIENCES, INC.
To: REVVITY HEALTH SCIENCES, INC.
Reel/Frame 067006/0297 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2021
From: FILER, CRIST
To: PERKINELMER HEALTH SCIENCES, INC.
Reel/Frame 055004/0371 →
Continuity (2)
Provisional Application 62965652 · Jan 24, 2020
Related Publication 20210230113A1 · Jul 29, 2021
References Cited (31)
US 9611213B2 · Brenneman et al. · 2017 [cited by applicant]
US 20170008868A1 · Dialer et al. · 2017 [cited by applicant]
WO WO2012011112 · 2012 [cited by applicant]
WO WO2017008136 · 2017 [cited by applicant]
WO WO2017178807 · 2017 [cited by applicant]
WO WO2020104796A1 · 2020 [cited by examiner]
WO WO2020185661A1 · 2020 [cited by examiner]
WO WO2021046636A1 · 2021 [cited by examiner]
Ben-Shabat et al. J. Med. Chem. 2006, 49, 1113-1117. (Year: 2006). [cited by examiner]
Pitt et al. J. Labelled Cmpd 1975, 11(4), 551-575. (Year: 1975). [cited by examiner]
Haj et al. J. Pharmacol. Exp Ther. 2015, 355, 66-75. (Year: 2015). [cited by examiner]
International Preliminary Report on Patentability in International Appln. PCT/US2021/014606, dated Jul. 26, 2022, 13 pages. [cited by applicant]
Ben-Shabat et al., “New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity,” Journal of medicinal chemistry, Feb. 9, 2006, 49(3):1113-1117. [cited by applicant]
Blake et al., “Studies with deuterated drugs. Journal of Pharmaceutical Sciences,” Mar. 1, 1975, 64(3):367-391. [cited by applicant]
Filer, “Tritiated dihydro compounds employed as radioligand surrogates,” Journal of Labelled Compounds and Radiopharmaceuticals, Oct. 2011, 54(12):731-742. [cited by applicant]
Filipski et al., “Intestinal targeting of drugs: rational design approaches and challenges,” Current topics in medicinal chemistry, Apr. 1, 2013, 13(7):776-802. [cited by applicant]
Fukuto et al., “Determination of the mechanism of demethylenation of (methylenedioxy) phenyl compounds by cytochrome P450 using deuterium isotope effects,” Journal of medicinal chemistry, Sep. 1991, 34(9):2871-2876. [cited by applicant]
Gannes et al., “Natural abundance variations in stable isotopes and their potential uses in animal physiological ecology,” Comparative biochemistry and physiology Part A: Molecular & integrative physiology, Mar. 1, 1998… [cited by applicant]
Hanu et al., “Phytocannabinoids: a unified critical inventory,” Natural product reports, 2016, 33(12): 37 pages. [cited by applicant]
Kinney et al., “Discovery of KLS-13019, a cannabidiol-derived neuroprotective agent, with improved potency, safety, and permeability,” ACS medicinal chemistry letters, Apr. 14, 2016, 7(4):424-428. [cited by applicant]
Kushner et al., “Pharmacological uses and perspectives of heavy water and deuterated compounds,” Canadian journal of physiology and pharmacology, Feb. 1, 1999, 77(2):79-88. [cited by applicant]
Lammers et al., “Effect of intratumoral injection on the biodistribution, the therapeutic potential of HPMA copolymer-based drug delivery systems,” Neoplasia, Oct. 1, 2006, 8(10):788-795. [cited by applicant]
Mascal et al., “Synthetic, non-intoxicating 8, 9-dihydrocannabidiol for the mitigation of seizures,” Scientific reports, May 26, 2019, 9(1):1-6. [cited by applicant]
Mechoulam et al., “Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects,” Chemistry and physics of lipids, Dec. 31, 2002, 121(1-2): 10 pages. [cited by applicant]
Morales et al., “An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol,” Frontiers in pharmacology, Jun. 28, 2017, 8(422): 18 pages. [cited by applicant]
Raffa et al., “The First Approved “Deuterated” Drug: A Short Review of the Concept,” Pharmacology & Pharmacy, Oct. 23, 2018, 9(10):440-446. [cited by applicant]
Ujváry et al., “Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy,” Cannabis Cannabinoid Res 1: 14 pages. [cited by applicant]
Zamberletti et al., “Cannabidivarin treatment ameliorates autism-like behaviors and restores hippocampal endocannabinoid system and glia alterations induced by prenatal valproic acid exposure in rats,” Frontiers in cell… [cited by applicant]
Crombie et al., “Terpenylations using (R)-(−)-α-phellandrene. Synthesis of the (3 S, 4 R)-8, 9-dihydro-o-and-p-cannabidiols, their iso-THC's, and the natural dihydrochalcone (3 S, 4 R)-(+)-linderatin,” Journal of the Ch… [cited by applicant]
International Search Report and Written Opinion in International Appln. PCT/US2021/014606, dated Jul. 8, 2021, 21 pages. [cited by applicant]
Morales, P., et al., An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol, 8(422): 1-18, Jun. 28, 2017. [cited by applicant]